A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I).

Trial Profile

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 18 Mar 2017

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
  • Indications Hepatitis C; HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms TURQUOISE-I
  • Sponsors AbbVie; Genentech
  • Most Recent Events

    • 18 Mar 2017 Results (n=22) presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 14 Mar 2017 Results (n=22) of part Ib assessing the efficacy and safety of OBV/PTV/r + DSV with RBV in patients with HCV GT1/HIV-1 coinfection on a stable, DRV-containing ART regimen, published in the Journal of Infectious Diseases
    • 05 Dec 2016 Results of a pharmacokinetic substudy (n=22), published in the Antimicrobial Agents and Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top